(Q51371877)

English

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

scientific article published in November 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

type 2 diabetes

0 references

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

placebo-controlled trial

1 reference

based on heuristic

inferred from title

author name string

K Kaku

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

T Itayasu

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

S Hiroi

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

M Hirayama

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

Y Seino

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

publication date

1 November 2011

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

13

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

11

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

1028-1035

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Current antihyperglycemic treatment strategies for patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Fate of the beta-cell in the pathophysiology of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

GIP and GLP-1, the two incretin hormones: Similarities and differences

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Little enhancement of meal-induced glucagon-like peptide 1 secretion in Japanese: Comparison of type 2 diabetes patients and healthy controls

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Intact glucagon-like peptide-1 levels are not decreased in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Report of the committee on the classification and diagnostic criteria of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Pioglitazone: side effect and safety profile

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Report of the Committee on the classification and diagnostic criteria of diabetes mellitus

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01460.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01460.X

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

release_pah2nyfbdvcqtni7yqvlg74zyu

1 reference

https://api.fatcat.wiki/v0/release/pah2nyfbdvcqtni7yqvlg74zyu

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21682833

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51371877&oldid=1837648617"